Dr. Fleming on imaging agent 18F-rhPSMA-7.3 and SPOTLIGHT trial in prostate cancerMay 16th 2022
In the phase 3 SPOTLIGHT trial, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.
Niraparib/abiraterone regimen shows early efficacy signals in metastatic prostate cancerMay 14th 2022
A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.
Novel PET imaging agent 18F-rhPSMA-7.3 increases upstaging in recurrent prostate cancerMay 14th 2022
Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.
Understanding patterns in prostate genomic testing using SEER and GPS assayOctober 4th 2021
In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.
Phase 2b data point to safety, efficacy of focal therapy in intermediate-risk prostate cancerOctober 1st 2021
In a study presented at the 2021 AUA annual meeting, Behfar Ehdaie, MD, MPH, and colleagues assessed the efficacy of focal therapy in treating patients with grade group 2 or 3 prostate cancers.
Noninvasive miR Sentinel PCC4 Test accurately identifies prostate cancerSeptember 30th 2021
In a recent study presented at the 2021 AUA Annual Meeting, Laurence Klotz, MD, FRCSC, and a team of investigators determined the accuracy of the new miR Sentinel PCC4 Test, a urinalysis of low- to high-grade prostate cancer in men.
Dr. Gao on treating re-emerged PARPi-resistant prostate cancerSeptember 24th 2021
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
Dr. Shore on the benefits of starting darolutamide for patients with nmCRPCSeptember 22nd 2021
“The take-home message for all practicing urologists should be that if you have an nmCRPC patient, don't wait for them to develop mCRPC based on conventional imaging…We have 3 really efficacious level 1 evidence studies that have demonstrated the value for starting any of these 3 drugs,” says Neal D. Shore, MD.
Dr. Gao on study of resistance to PARP inhibitor olaparib in prostate cancerSeptember 22nd 2021
“In those resistance cells, there is a lot of senescence occurring there, so that provides some potential target…which can be used to improve those PARP inhibitor therapies,” says Allen C. Gao, MD, PhD.
Benefits of collecting and reporting smoking status in patients with GU cancerSeptember 22nd 2021
"In the clinic, I think the biggest benefit, at least immediately, is that by asking and trying to figure out what a patient's tobacco use history is, you can help with quitting,” says Richard Matulewicz, MD, MS.
Study finds focal therapy a safe option for treating intermediate-risk prostate cancerSeptember 21st 2021
“Although [whole-gland] treatments are very successful, from the oncologic perspective, our goal was to develop and test a new treatment modality in which we treat only the area with the significant cancer using focused ultrasound in the MRI gantry,” says Behfar Ehdaie, MD, MPH.